Loading clinical trials...
Loading clinical trials...
A Multinational, Prospective, Open-label, Roll-over Study (LIBERTY) to Provide Post-trial Access to Treatment for Patients With Haemophilia A Who Have Completed a Previous Trial With Efanesoctocog Alfa
Conditions
Interventions
Efanesoctocog alfa
Locations
24
Bulgaria
Sobi Investigational Site
Plovdiv, Bulgaria
Sobi Investigational Site
Sofia, Bulgaria
Sobi Investigational Site
Bordeaux, France
Sobi Investigational Site
Brest, France
Sobi Investigational Site
Bron, France
Sobi Investigational Site
Le Kremlin-Bicêtre, France
Start Date
March 6, 2025
Primary Completion Date
March 1, 2027
Completion Date
March 1, 2027
Last Updated
April 20, 2026
Lead Sponsor
Swedish Orphan Biovitrum
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions